Merck Serono Partners with Sutro Biopharma

Merck Serono, the biopharma division of German drug giant Merck, and Sutro Biopharma have announced a new collaboration and license agreement to develop antibody drug conjugates (ADCs). The two organisations will work alongside each other, using Sutro’s cell-free protein synthesis platforms, to discover and develop multiple ADCs, antibodies linked to cytotoxic drugs for increased targeted

Continue Reading